Galectin-3 not Galectin-9 as a candidate prognosis marker for hepatocellular carcinoma

Galectin-3 not Galectin-9 as a candidate prognosis marker for hepatocellular carcinoma:



Background
Galectins (Gal) are a family of protein that bind to the β-galactoside of glycoproteins. It modulates a variety of biological functions, such as tumor growth, angiogenesis and tumor metastasis. A series of experimental and clinical evidences have been reported to support a correlation between galectin expressions and neoplastic transformation, progression and prognosis. The objective of this study was to estimate the expression of Gal-3 and Gal-9 in order to evaluate their relation to hepatocellular carcinoma (HCC) -related clinical features and their prognostic values.


Methods
We evaluated Gal-3 and Gal-9 expression in 247 HCC patients by a tissue microarray immunohistochemistry method, then analyzed the relationship between expression levels of Gal-3 and Gal-9 protein and tumor parameters or clinical outcomes.


Results
The Gal-3 expression was significantly higher in tumor tissues compared with adjacent non-tumor tissues (P